Alienating evidence based medicine vs. innovative medical device marketing: A report on the evidence debate at a Wounds conference

Social Science and Medicine

Volumn 74, Issue 12, 2012, Pages 2046-2052

  Madden, Mary ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Chronic wounds; Evidence based medicine; Medical anthropology; Medical devices; Nursing; Pharmaceutical marketing; Sociology of science and technology; UK

Indexed keywords

ANTIINFECTIVE AGENT;

HEALTH SERVICES; MARKETING; PHARMACEUTICAL INDUSTRY; PRIVATIZATION;

ARTICLE; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; INTERMETHOD COMPARISON; MARKETING; MEDICAL DEVICE; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; TREND STUDY; UNITED KINGDOM; WOUND CARE; WOUND DRESSING; WOUND INFECTION;

ATTITUDE OF HEALTH PERSONNEL; CONGRESSES AS TOPIC; DIFFUSION OF INNOVATION; EQUIPMENT AND SUPPLIES; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MARKETING; PRIVATIZATION; STATE MEDICINE; WOUNDS AND INJURIES;

UNITED KINGDOM;

EID: 84860440447     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2012.02.026     Document Type: Article

References (85)

1. Abraham J. The pharmaceutical industry as a political player. The Lancet November 9 2002, 360.
2. Abraham J., Davis C. Testing times: the emergence of the Practocol disaster and its challenge to British drug regulation in the modern period. Social History of Medicine 2006, 19:127-147.
3. Abraham, J., & Davis, C. (2011). Pharmaceutical fallacy: the mis-direction of regulation, innovation and public health. Paper presented at symposium, Pharmaceuticals and Society: Power Promises and Prospects, University of Warwick, 16th December.
4. Angell M. The truth about the drug companies: How they deceive us and what to do about it 2005, Random House, New York.
5. Applbaum K. How to organize a psychiatric congress. Anthropological Quarterly 2004, 77(2):303-310.
6. Applbaum K. Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine and Psychiatry 2009, 33:185-215.
7. Ashby R.L., Bland J.M., Cullum N., Dumville J.C., Hall J., Kang'ombe A.R., et al. Reflections on the recommendations of the EWMA Patient Outcome Group document. Journal of Wound Care 2010, 19(7):282-285.
8. Beasley, A., & Blenman, J. (2010). Tolerance in practice: evaluation of the effectiveness of a new product, assessing both the patient's tolerance of the treatment and the practitioner's acceptance and tolerance of the bandage system. Papers presented at plenary session in association with 3M Health Care. Wounds UK 2010, 16th November.
9. BIS (Department of Business Innovation and Skills) Strength and opportunity: The landscape of the medical technology, medical biotechnology and industrial biotechnology sectors in the UK 2010, HM Government, London.
10. BNF (British National Formulary) Section A8.2 2011, BMJ Group and Pharm Press, Retrieved 03.05.11 from. http://www.bnf.org.
11. Brown N., Rappert B., Webster A. Introducing contested futures: from looking into the future to looking at the future. Contested futures: A sociology of prospective techno-science 2000, Ashgate, Aldershot.
12. Browne N., Grocott P., Cowley S. The wound dressing supply chain within England's National Health Service: unravelling the context for users. Journal of Nursing Management 2004, 12:51-61.
13. Chaby G., Senet P., Vaneau M., Martel P., Guillaume J.-C., Meaume S., et al. Dressings for acute and chronic wounds: a systematic review. Archives of Dermatology 2007, 143(10):1297-1304.
14. Chalmers I. What do I want from health research and researchers when I am a patient?. British Medical Journal 1995, 310:1315-1318.
15. Chartered Institute of Marketing The real NHS: The benefits of a marketing approach 2008, Retrieved 09.09.11 from. http://www.cim.co.uk/filestore/resources/agendapapers/therealnhs.pdf.
16. Cochrane Wounds Group Retrieved 15.02.11 from. http://wounds.cochrane.org/.
17. Cohen D., Billinglsey M. Europeans are left to their own devices. British Medical Journal 2011, 342:d2748.
18. Wound care handbook 2010-2011 2010, Mark Allen Healthcare, London. 3rd ed. T. Cowan (Ed.).
19. Crigger N., Barnes K., Junko A., Rahal S., Sheek C. Nurse practitioners' perceptions and participation in pharmaceutical marketing. Journal of Advanced Nursing 2009, 65(3):525-533.
20. Davies, S. (2010). How in vitro studies of fibroblasts can help us to gain a better understanding of how dressings work: are all dressings the same? Paper presented at plenary session in association with Urgo Limited. Wounds UK 2010, 16th November.
21. DH (Department of Health) Prescription cost analysis England 2009 2009, DH, London, Retrieved 02.02.11 from. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england--2009.
22. DH (Department of Health) Response to opinion of Stephen Cragg published by 38 degrees, on the application of procurement and competition law to the NHS 2011, DH, London, Retrieved 26.03.12 from. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_129883.pdf.
23. Di Mario C., James S., Dudek D., Sabate M., Degertekin M. Commentary: the risk of over-regulation. British Medical Journal 2011, 342:d3021.
24. Dumville J.C., Petherick E.S., Cullum N. When will I see you again? The fate of research findings from international wound care conferences. International Wound Journal 2008, 5(1):26-32.
25. Dumville J.C., Petherick E.S., O'Meara S., Raynor P., Cullum N. How is research evidence used to support claims made in advertisements for wound care products?. Journal of Clinical Nursing 2009, 18(10):1422-1429.
26. Elliott C. White coat, black hat: Adventures on the dark side of medicine 2010, Beacon Press, Boston.
27. Emerson R.M., Fretz R.I., Shaw L.L. Writing ethnographic fieldnotes 1995, University of Chicago Press, Chicago.
28. Faulkner A. Device or drug? Governation of tissue engineering. Medical technology into healthcare and society 2009, 159-187. Palgrave Macmillan, Basingstoke.
29. Firth J., Nelson E.A., Hale C., Hill J., Helliwell P. A review of design and reporting issues in self-reported prevalence studies of leg ulceration. Journal of Clinical Epidemiology 2010, 63:907-913.
30. Gigerenzer G. Reckoning with risk: Learning to live with uncertainty 2002, Penguin, London.
31. GMC (General Medical Council) Maintaining and improving your performance. Good Medical Practice 2010, 14f. Retrieved 02.02.11 from. http://www.gmc-uk.org/guidance/good_medical_practice/maintaining_good_medical_practice_performance.asp.
32. Gottrup F. Evidence is a challenge in wound management. International Journal of Lower Extremity Wounds 2006, 5(2):74-75.
33. GRADE Working Group Grading quality of evidence and strength of recommendations. British Medical Journal 2004, 328:1490.
34. Graham I.D., Harrison M.B., Nelson E.A., Lorimer K., Fisher A.R. Prevalence of lower-limb ulceration: a systematic review of prevalence studies. Advances in Skin & Wound Care 2003, 16(6):305-316.
35. Gray, D. (2010). The role of different professionals in the management of chronic wounds: the role of the tissue viability nurse specialist. Paper presented at, Wounds UK 2010. 17th November.
36. Greenhalgh T., Robert G., Macfarlane F., Bate P., Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. The Milbank Quarterly 2004, 82(4):581-629.
37. Harding, K., White R., & Jeffrey, S. (2010). What is acceptable evidence for medical devices in the wound care field. Papers presented at parallel session. Wounds UK 2010, 15 November.
38. Haynes R.B. Loose connections between peer reviewed clinical journals and clinical practice. Annals of Internal Medicine 1990, 113:724-728.
39. Health Committee The influence of the pharmaceutical company 2005, HC 42-I [Incorporating HC 1030-i-iii], The Stationery Office Limited, London.
40. InPharm.com UK trade associations form new life sciences lobbying group 2011, Retrieved 09.09.11from. http://www.inpharm.com/news/110112/lifesciencesuk-abpi-bia-abhi-bivda.
41. Joyce K., Loe M. A sociological approach to ageing, technology and health. Sociology of Health and Illness 2010, 32(2):171-180.
42. Kaltenthaler E., Withfield M.D., Walters S.J., Akehurst R.L., Paisley S. UK, USA and Canada: how do their pressure ulcer prevalence and incidence data compare?. Journal of Wound Care 2001, 10(1):530-535.
43. Lakoff A. Pharmaceutical reason: Knowledge and value in global psychiatry 2007, Cambridge University Press, Cambridge.
44. Lamb K., Stubbs N., Dumville J., Cullum N., O'Meara S. Wounds research for patient benefit: a five year programme of research in wound care. European Wound Management Association Journal 2011, 11(2):43-46.
45. Langley C., Parkinson S. Science and the corporate agenda: The detrimental effects of commercial influence on science and technology 2009, Scientists for Global Responsibility (SGR), Folkestone, Retrieved 02.02.11 from. http://www.statewatch.org/news/2009/oct/scientists-for-global-responsibillty-report.pdf.
46. Leaper D. Evidence based wound care in the UK. International Wound Journal 2009, 6(2):89-91.
47. Leys C., Player S. The Plot against the NHS 2011, The Merlin Press Ltd, Pontypool.
48. Lomas J. The in-between world of knowledge brokering. British Medical Journal 2007, 334:129-134.
49. McInnes E., Jammali-Blasi A., Bell-Syer S.E.M., Dumville J.C., Cullum N. Support surfaces for pressure ulcer prevention. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD001735. 10.1002/14651858.CD001735.pub4.
50. MeReC Evidence-based prescribing of advanced wound dressings for chronic wounds in primary care. MeReC Bulletin 2010 July, 21(01). June 2010 Liverpool, NHS National Prescribing Centre.
51. MHRA (The Medicines and Healthcare products Regulatory Agency) How we regulate devices 2011, Retrieved 02.02.11 from. http://www.mhra.gov.uk/Howweregulate/Devices/index.htm.
52. Michaels J.A., Campbell B., King B., Palfreyman S.J., Shackley P., Stevenson M. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). British Journal of Surgery 2009, 96(10):1147-1156.
53. Montgomery K. How doctors think: Clinical judgment and the practice of medicine 2006, Oxford University Press, New York.
54. Oldani M.J. Thick prescriptions: toward and interpretation of pharmaceutical sales practices. Medical Anthropology Quarterly 2004, 18(3):325-356.
55. O'Meara S., Cullum N.A., Nelson E.A. Compression for venous leg ulcers. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD000265.
56. Oswald N., Bateman H. Treating individuals according to evidence: why do primary care practitioners do what they do?. Journal of Evaluation in Clinical Practice 2000, 16(2):139-148.
57. Polak P., Clift M., Bower L., Sprange K. Buyer's guide: Advanced wound dressings 2008 October, CEP08038, NHS Centre for Evidence-based Purchasing, London.
58. Pollock A.M. NHS plc-The privatisation of our health care 2004, Verso, London.
59. Pollock N., Williams R. The business of expectations: how promissory organizations shape technology and innovation. Social Studies of Science 2010, 40(4):525-548.
60. Porter T. Trust in numbers: Objectivity in science and public life 1995, Princeton University Press, Princeton, NJ.
61. Prosser H., Almod S., Walley T. Influences on GPs' decisions to prescribe new drugs. Family Practice 2003, 20:61-68.
62. Radcliffe M. Doctors and nurses: new game, same result. British Medical Journal 2000, 320(7241):1085.
63. Rawlins M. Harveian Oration 2008: De testimonio: On the evidence for decisions about the use of therapeutic interventions 2008, Royal College of Physicians, London.
64. Reiber G. The epidemiology of diabetic foot problems. Diabetic Medicine 1996, 13(Suppl. 1):S6-11.
65. Robson M.C., Cooper D.M., Aslam R., Gould L.J., Harding K.G., Margolis D.J. Guidelines for the treatment of venous ulcers. Wound Repair and Regeneration 2006, 14(6):649-662.
66. Sackett D.L., Rosenberg W.M.C., Muir Gray J.A., Haynes R.B., Richardson W.S. Evidence-based medicine: what it is and what it isn't. British Medical Journal 1997, 312:71.
67. Sharp B., Dawes J. What is differentiation and how does it work?. Journal of Marketing Management 2001, 200(17):739-759.
68. Shils E. Social inquiry and the autonomy of the individual. Social research ethics 1982, Macmillan, London. Bulmer (Ed.).
69. Shorney R.H., Rush D. Ethical sponsorship boosts learning and will benefit all. Wounds UK 2006, 3(1):103.
70. Sismondo S. Ghosts in the machine. Publication planning in the medical sciences. Social Studies of Science 2009, 39:171-198.
71. Smith M. As products and positive outcomes proliferate, bioengineered wound care gains acceptance, converts skeptics. The Free Library 2009, August 24, Retrieved 17.01.11 from, Products and Positive Outcomes Proliferate, Bioengineered Wound.-a01073977624. http://www.thefreelibrary.com/As.
72. Snyder, R. J., Harding, K., & Barrett, S. (2010). An introduction to diagnostics in the UK. Papers presented at plenary session in association with Systagenix. Wounds UK 2010, 15th November.
73. Spicker P. Ethical covert research. Sociology 2011, 45(1):118-133.
74. Steed D.L., Attinger C., Colaizzi T., Crossland M., Franz M., Harkless L., et al. Guidelines for the treatment of diabetic ulcers. Wound Repair and Regeneration 2007, 14:680-692.
75. Stein L.I. The doctor-nurse game. Archives of General Psychiatry 1967, 16(6):699-703.
76. Sufrin C.B. The " exhibit mall" at the American College of Obstetricians and Gynecologists annual clinical meeting: reflections on consumerism and medicine. Obstetrics & Gynecology 2008, 112(6):1355-1359.
77. The AGREE Collaboration Appraisal of guidelines for research & evaluation 2001, Retrieved 26.03.2012 from. http://www.agreetrust.org/resource-centre/the-original-agree-instrument/.
78. Thompson C., Cullum N., McGaughan D., Sheldon T., Raynor P. Nurses, information use, and clinical decision making-the real world potential for evidence-based decisions in nursing. Evidence Based Nursing 2004, 7:68-72.
79. Timmermans S., Berg M. The gold standard: The challenge of evidence-based medicine and standardization in health care 2003, Temple University Press, Philadelphia.
80. Van Lente H. Forceful futures: from promise to requirement. Contested futures: A sociology of prospective techno-science 2000, Ashgate, Aldershot. Brown (Ed.).
81. Walton D. Fundamentals of critical argumentation 2006, Cambridge University Press, New York.
82. Wazana A. Physicians and the pharmaceutical industry. Journal of the American Medical Association 2000, 283:373-380.
83. Whiting L., Gleghorn L., Shorney R.H. Developing a non-clinical skill set for tissue viability. Wounds UK 2008, 4(1):41-48.
84. Wiegand, C. (2010). The safety and effectiveness of antimicrobial treatments: managing the at-risk patient. Paper presented at plenary session in association with Activa Healthcare, Wounds UK 2010, 15th November.
85. Winter G.D. Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig. Nature 1962, 193:293-294.